Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial.

ABSTRACT:

SUBMITTER: Krop IE 

PROVIDER: S-EPMC5524539 | biostudies-literature | 2016 Jun

REPOSITORIES: biostudies-literature